RxDoctor Payments DataLook up a doctor →

Adnan Subei, DO

Neurology · Dallas, TXNPI 1962722876

Payments from drug & device makers

$3,108,238in general payments, 2019–2025

Across 870 payments — averaging $3572.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.4M
  • Sanofi$219K
  • EMD Serono, Inc.$132K
  • TG Therapeutics, Inc.$100K
  • Amgen$70K
  • AstraZeneca$60K
  • plus $93K from 41 others
$13,657in research payments, 2019–2025

Across 27 payments — averaging $505.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$8K
  • Novartis$3K
  • Sanofi US Services Inc.$2K
  • Sanofi$660
  • Novartis Pharma AG$77

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis70$2,434,310
Sanofi50$218,985
EMD Serono, Inc.106$132,431
TG Therapeutics, Inc.94$99,651
Amgen(2 entities)86$69,729
AstraZeneca111$59,779
Biogen96$57,558
E.r. Squibb & Sons, L.L.C.27$23,063
Bristol Myers Squibb27$6,995
Cycle Pharmaceuticals Inc2$1,189
AbbVie39$705
Genentech USA, Inc.21$593
UCB, Inc.13$320
Eisai Inc.10$293
Acadia Pharmaceuticals Inc11$264
Merz Pharmaceuticals, LLC7$206
Neurocrine Biosciences, Inc.8$196
Pfizer12$194
Teva Pharmaceuticals USA, Inc.5$172
Argenx US, Inc.5$170
Lilly USA, LLC8$158
Lundbeck LLC6$122
Octapharma USA, Inc.5$109
Ipsen Biopharmaceuticals, Inc4$102
Grifols USA, LLC4$90
Johnson & Johnson(2 entities)5$85
Vanda Pharmaceuticals Inc.3$81
Axsome Therapeutics, Inc.3$72
Jazz Pharmaceuticals Inc.3$58
Genentech, Inc.3$57
Neurelis, Inc.2$52
Catalyst Pharmaceuticals, Inc.3$51
Takeda Pharmaceuticals U.S.A., Inc.2$47
SK Life Science, Inc.2$47
Hospira, Inc.2$36
Scilex Pharmaceuticals Inc.2$32
Immedica Pharma US, Inc.1$31
GE HealthCare2$31
Acorda Therapeutics, Inc2$29
NS Pharma, Inc.1$22
CSL Behring1$22
Life Molecular Imaging Ltd1$20
Corium, LLC1$20
Alnylam Pharmaceuticals Inc.1$16
Sumitomo Pharma America, Inc.1$15
Globus Medical1$15
Mallinckrodt Hospital Products Inc.1$14

How this compares

$3,108,238 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$179,961
Medicare patients
320
Services billed
8,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →